New York, USA, June 8— GBI, a leading healthcare intelligence solutions provider, announced the launch of its new, global pharmaceutical API platform. Concurrently, GBI announced its first client for this data service – a top-five pharmaceutical firm which will leverage the API database for business development, competitive intelligence, and regulatory monitoring. Under the collaboration terms, GBI’s API platform will be fully integrated into the client’s systems and cover global drug registrations, pipelines, and other important drug attributes. The API platform builds upon more than 18 years of experience and complements GBI’s interface-driven SOURCE system, which remains a gold standard for pharmaceutical companies worldwide.
Founded in 2002, GBI has built a portfolio of market intelligence solutions covering pharmaceuticals and medical devices. GBI’s value-added industry information, news, analytics, and data services enable its clients to make real-time, data-driven decisions.
GBI has offices in Shanghai, Beijing, and Washington D.C.